Study Selection
• The criteria for screening of the articles were as follows:
-Population: patients with genotype 1 HCV, with or without concomitant liver diseases -Interventions of interest (applied to economic evaluations only): interferon-free and interferon-containing regimens, including combinations of the treatments listed above -Study type of interest: economic evaluations -Exclusionary terms: irrelevant publication types, including nonsystematic reviews, comments, editorials, letters, case reports, or studies in animals but not humans
• One researcher reviewed titles and abstracts for potential relevance (Level 1 screen) and reviewed the potentially relevant full-text articles (Level 2 screen). A second researcher resolved any uncertainty about study inclusion, checked a random selection (5%) of identifi ed titles and abstracts and full-text articles, and confi rmed eligibility of all studies selected after the Level 2 screen.
• For each eligible study, one researcher extracted the data of interest, while another researcher verifi ed the data with the original sources.
Quality Assessment
• All included economic evaluations were assessed using the quality criteria presented in the National Institute for Health and Care Excellence (NICE) single technology appraisal template.
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RESULTS
• Figure 1 shows the results of the systematic review.
• Most models (n = 24) used a Markov structure; decisionanalytic models were also common (n = 10) ( Figure 2 ).
• Most models (n = 28) used a lifetime horizon. All models used long-term time horizons, with the smallest time horizon being 20 years.
• Many publications did not report the time horizon used in their models (n = 14) or the model structure (n = 7).
• Most analyses were performed in the United States (n = 13), the UK (England, Wales, and Scotland) (n = 13), and Germany (n = 7) ( Figure 3 ).
• Although this literature search was designed to identify data on any of the new interferon-free regimens, all of the included economic evaluations were for the existing interferon-containing regimens (including more recently approved treatment combinations).
-The models did not account for the possibility of benefi ts caused by reduced transmission of HCV or the potential costs of HCV reinfection. Doing so would require much longer-term data that may be diffi cult to accurately incorporate in a model.
-The models did not incorporate patient factors, such as alcohol consumption or duration of infection, which may have an infl uence on disease progression.
-The modelling of subgroups may have been insuffi cient to accurately capture the incremental costs and benefi ts within treatment groups.
-As understanding of HCV grows, so does the knowledge of patient and genetic factors that may infl uence disease progression or may be important in predicting a patient's response to treatment. These factors were not taken into account in previous models or studies and therefore may be diffi cult to incorporate in the economic models.
-Incorporating more detailed patient factors and patient subgroups in the economic models should give a more accurate estimate of cost-effectiveness.
• The recent NICE submissions provided additional detail and related criticism on the submitted models:
-The telaprevir submission made generalisations for the compensated cirrhosis population that were not comparable with the UK population:
• The number of people classifi ed as having cirrhosis may not have been suffi cient to refl ect the higher proportion of patients in the UK with cirrhosis.
• It is uncertain what effect the larger cirrhosis population in the UK would have on the incremental cost-effectiveness ratios (ICERs). This could decrease the ICER, because patients are at greater risk for poor outcomes, or increase the ICER, because patients with cirrhosis tend to respond less well to treatment.
-The telaprevir submission unintentionally allowed transition probabilities to vary with age rather than being fi xed to age at the time of treatment.
-Trials used in the boceprevir submission used different defi nitions of early responders and stopping rules for treatment-naïve and treatment-experienced patients than those in the label.
-The methods for deriving effi cacy estimates in the boceprevir submission were not clearly described.
CONCLUSIONS
• The systematic literature review identifi ed 44 economic evaluations and 17 HTA documents.
• The majority of economic evaluations were of interferon-containing regimens; were performed using lifetime horizon Markov models; and were performed in the United States, the UK, or Germany.
• There are numerous recent economic models; however, these have generally adhered to previous iterations of HCV models or models used in previous HTA submissions and have not evolved with our knowledge of the disease.
• In light of upcoming treatment alternatives, model refi nement may be necessary to capture the increasingly complex treatment decisions that will be required. Enhanced utility and cost studies and more advanced modeling approaches may be needed.
REFERENCES
Please see handout for complete reference list. • The most common comparisons were between the newer treatments of boceprevir triple therapy with PEG-IFN and ribavirin alone (n = 8) and telaprevir triple therapy with PEG-IFN and ribavirin alone (n = 11) ( Table 1 ).
CONTACT INFORMATION
• The other models were mainly comparisons of PEG-IFN plus ribavirin: different PEG-IFNs (PEG-IFN alfa-2a versus PEG-IFN alfa-2b), different modes of treatment, or different treatment schedules.
• Two recent NICE submissions were included: telaprevir triple therapy (with PEG-IFN plus ribavirin) and boceprevir triple therapy. They used different models; however, their structures and some inputs were based on previous appraisals for PEG-IFN plus ribavirin.
DISCUSSION
• The following limitations in the included economic evaluations may have affected the cost-effectiveness outcomes:
-Many models were based on previous iterations of economic models or previous HTA submissions, including model structures and/or inputs.
-The models may not have adequately captured all health benefi ts and costs in their quality-adjusted life-year calculations (e.g., drug wastage costs).
-Many models did not consider response-guided therapy, which may impact costs of treatment by shortening treatment duration for patients who achieve an early response or who do not respond to treatment.
